J&J Plans To File Yondelis NDA Based On Phase II Data
This article was originally published in The Pink Sheet Daily
Executive Summary
The firm plans to submit trabectedin for soft tissue sarcoma once a Phase III confirmatory trial is underway.
You may also be interested in...
J&J Zarnestra Receives “Not Approvable” Letter From FDA
Oral leukemia agent is not approvable based on Phase II clinical trials, the agency said. J&J maintains it is committed to developing tipifarnib and will determine “appropriate next steps.”
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.
CinFina Pushes Early Work In Obesity In Hopes Of A Deal
Emerging Company Profile: CinFina is advancing two novel mechanisms of action in obesity as monotherapies and in combination with GLP-1s.